Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Amikacin · Amikin, Amikin In Sodium Chloride 0.9% In Plastic Container

Small molecule · developed by Insmed

Approved FDA, Sep 2018
INSM Developer
9 Registered trials

What is Amikacin?

Amikacin liposome inhalation suspension is an aminoglycoside antibacterial delivered as a liposomal dispersion by nebulization. It is studied in Mycobacterium avium complex lung disease and in patients with cystic fibrosis.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Amikin, Amikin In Sodium Chloride 0.9% In Plastic Container, Arikayce, ALIS, LAI 590, BAY 41-6551, NSC-177001, ARIKAYCE, ARIKACE
Drug type
Small molecule
Therapy area
Infectious disease, Respiratory
Developer
Insmed Inc (INSM)
FDA status
Approved as Amikin, Amikin In Sodium Chloride 0.9% In Plastic Container, Arikayce (September 28, 2018), NDA207356 · FDA label
UNII
84319SGC3C

✅ FDA-approved uses

From the indications section of the FDA label (version of Aug 4, 2026). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT04677569 Phase 3 Mycobacterium Infections, Nontuberculous Completed INSM
NCT02628600 Phase 3 NTM Lung Infection Due to MAC Completed INSM
NCT02344004 Phase 3 Mycobacterium Infections, Nontuberculous Completed INSM
NCT01316276 Phase 3 Cystic Fibrosis Completed INSM
NCT03038178 Phase 2 Mycobacterium Infections, Nontuberculous Completed INSM
NCT01315236 Phase 2 Mycobacterium Infections, Nontuberculous Completed INSM
NCT03905642 Phase 2 Cystic Fibrosis Completed INSM
NCT00777296 Phase 1/2 Cystic Fibrosis Completed INSM
NCT06238856 Phase 1 Cystic Fibrosis Completed INSM

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Cystic FibrosisMycobacteria, AtypicalMycobacterium Infections, NontuberculousNTM Lung Infection Due to MAC

More from Insmed

Sources

Updated Oct 18, 2026. Something wrong or missing? Report it on the INSM page.

Follow INSM, the company behind Amikacin

See INSM's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

INSM catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.